Eli Lilly and Co. (LLY) Earns Buy Rating from Leerink Swann
Eli Lilly and Co. (NYSE:LLY)‘s stock had its “buy” rating reissued by Leerink Swann in a research note issued to investors on Sunday. They presently have a $103.00 price target on the stock. Leerink Swann’s target price would suggest a potential upside of 25.47% from the stock’s current price.
LLY has been the subject of several other reports. BMO Capital Markets restated a “buy” rating and set a $94.00 price objective on shares of Eli Lilly and in a research note on Monday, October 3rd. JPMorgan Chase & Co. upgraded shares of Eli Lilly and from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $92.00 to $95.00 in a research note on Thursday, September 8th. Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Wednesday. Jefferies Group reaffirmed a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a report on Wednesday, September 14th. Finally, SunTrust Banks Inc. reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Wednesday, June 15th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $97.06.
Eli Lilly and (NYSE:LLY) opened at 82.09 on Friday. Eli Lilly and has a 52-week low of $67.88 and a 52-week high of $88.16. The company has a market cap of $86.83 billion, a price-to-earnings ratio of 35.38 and a beta of 0.17. The firm’s 50-day moving average is $79.44 and its 200 day moving average is $77.49.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/09/eli-lilly-and-co-lly-earns-buy-rating-from-leerink-swann.html
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, meeting the consensus estimate of $0.86. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The business earned $5.40 billion during the quarter, compared to analysts’ expectations of $5.14 billion. During the same period in the previous year, the business posted $0.90 EPS. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. On average, equities research analysts predict that Eli Lilly and will post $3.59 EPS for the current fiscal year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of the company’s stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $82.94, for a total value of $17,002,700.00. Following the transaction, the insider now owns 125,775,804 shares of the company’s stock, valued at $10,431,845,183.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Donald A. Zakrowski sold 1,213 shares of the company’s stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $83.16, for a total transaction of $100,873.08. Following the completion of the transaction, the insider now directly owns 1,300 shares in the company, valued at approximately $108,108. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Argent Trust Co raised its stake in shares of Eli Lilly and by 0.3% in the second quarter. Argent Trust Co now owns 4,184 shares of the company’s stock worth $329,000 after buying an additional 12 shares during the period. Jackson Grant Investment Advisers Inc. raised its stake in shares of Eli Lilly and by 0.7% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the company’s stock worth $308,000 after buying an additional 26 shares during the period. Wagner Bowman Management Corp raised its stake in shares of Eli Lilly and by 0.3% in the second quarter. Wagner Bowman Management Corp now owns 9,672 shares of the company’s stock worth $761,000 after buying an additional 29 shares during the period. Benjamin F. Edwards & Company Inc. raised its stake in shares of Eli Lilly and by 0.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,305 shares of the company’s stock worth $260,000 after buying an additional 31 shares during the period. Finally, Mycio Wealth Partners LLC raised its stake in shares of Eli Lilly and by 1.3% in the second quarter. Mycio Wealth Partners LLC now owns 2,431 shares of the company’s stock worth $191,000 after buying an additional 32 shares during the period. 74.96% of the stock is currently owned by institutional investors.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.